Crysvita approval marks a major advancement as the European Commission expands access to treatment for infants with X-linked hypophosphataemia. Kyowa Kirin EMEA confirmed the approval for Crysvita® (burosumab). The decision allows treatment for infants aged one month to one year. Moreover, the approval applies across the European Union and European Economic Area.
The announcement of the expansion was made by Kyowa Kirin EMEA, which is a subsidiary of Kyowa Kirin Co., Ltd. This decision is important in terms of ensuring early treatment for this particular rare genetic condition. In addition to that, the doctors can start treating patients earlier.
“For families affected by XLH, the impact of the disease can begin in the earliest months of a child’s life,” said Myriam Hakim, Regional Franchise Head, Kyowa Kirin EMEA. “This approval means healthcare professionals can now consider treatment with burosumab from as young as one month of age, creating an opportunity to address the disease earlier than ever before. It represents an important step forward for infants living with XLH and the families who care for them.”
Crysvita Expansion Supports Earlier XLH Treatment for Infants
X-Linked Hypophosphatemia is a condition that is progressive and lifelong. It results in phosphate losses and impaired bone mineralization. Consequently, it leads to skeletal malformation and difficulties in growth. The symptoms are usually observed during infancy and early childhood stages. Thus, early detection and treatment are essential.
This authorization was based on the positive opinion of the CHMP of the EMA. Also, this decision is backed by evidence obtained in the course of the BUR-CL207 clinical trial. It examined the safety, tolerance, and efficacy in infants. It was concluded that safety results were in line with earlier studies.
“XLH is a progressive disorder in which manifestations can begin during infancy, affecting skeletal development from the earliest stages of life. The approval of a treatment option for infants is an important milestone, as it enables the initiation of evidence-based therapy earlier in the disease course, with the goal of limiting disease progression and improving long-term patient outcomes,” said Prof. Agnès Linglart, AP-HP and Paris Saclay University.
By expanding to these indications, approval for Crysvita provides earlier treatment for patients. Furthermore, it emphasizes the need for timely medical intervention. As a result, both patients and healthcare professionals will have more treatment choices available for babies. Moreover, the approval extends the orphan market exclusivity period of the treatment in Europe. Orphan status is now available until February 2030.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
